Actively Recruiting
GT201 Injection For The Treatment Of Advanced Solid Tumors
Led by Grit Biotechnology · Updated on 2026-04-27
18
Participants Needed
4
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Expected to complete 7 to 18 evaluable subjects (patients with advanced solid tumors)，3 dose groups.A modified "3+3" dose-escalation design is utilized,This includes both accelerated dose escalation and traditional "3+3" dose escalation.The first dose group is accelerated titration,The first dose group is an accelerated titration of 1 to 6 evaluable subjects;The second and third dose groups are based on the traditional "3+3" dose-escalation principle,The second and third dose groups are based on the traditional "3+3" dose-escalation principle, with 3 to 6 evaluable subjects enrolled respectively.
CONDITIONS
Official Title
GT201 Injection For The Treatment Of Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ability to understand study requirements and provide written informed consent
- Confirmed diagnosis of malignancy by histology or cytology
- At least one resectable lesion not treated with radiation or local therapies, suitable for tissue collection for lymphocyte preparation
You will not qualify if you...
- Active autoimmune disease or history requiring systemic steroid or immunosuppressive therapy (>10 mg/day prednisone or equivalent)
- Arterial or venous thrombotic events within 3 months prior to enrollment (e.g., stroke, deep vein thrombosis, pulmonary embolism)
- Refractory or intractable epilepsy, poorly controlled hydrothorax, ascites, pericardial effusion, or contraindications to IL-2
- Participation in other clinical trials within 4 weeks prior to first dose or planned simultaneous participation
- Previous allogeneic bone marrow transplant or organ allograft
- History of hypersensitivity to study drug components including tumor infiltrating lymphocytes, cyclophosphamide, fludarabine, IL-2, DMSO, human serum albumin, dextran-40, or certain antibiotics
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
The fifth medical center of the General Hospital of the Chinese people's Liberation Army
Beijing, Beijing Municipality, China
Actively Recruiting
2
Union Hospital Tongji Medical College Huazhong University Of Science And Technology
Wuhan, Hubei, China
Actively Recruiting
3
Shandong Cancer Hospital
Jinan, Shandong, China
Actively Recruiting
4
West China Hospital Sichuan University
Chengdu, Sichuan, China, 610000
Actively Recruiting
Research Team
Y
Yongsheng Wang, PHD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here